MDoutlook Oncology Intelligence: Changing Paradigms in the Treatment of Metastatic Breast Cancer by European Oncologists

March 18th, 2011

A number of current events are going to have a significant impact on the treatment of metastatic breast cancer in Europe: the EMA has recently reduced the marketing approval for bevacizumab and new positive data from the EMBRACE trial (eribulin in the recurrent setting) were made available.

MDoutlook launched a Quick Poll™ among its 12,000+ European medical oncology members to determine how these events are and will be affecting clinical practice. Responses from 13 countries (>60% of responses were from the 5-EU) show the following:
Initial uptake in usage of eribulin will be stronger in later lines of treatment, although a majority of oncologists will begin using eribulin in the 2nd line for some of their metastatic breast cancer patients (see figure below)
• It is widely believed that eribulin will soon prove to be effective as an initial treatment for metastatic breast cancer with less acceptance as a neoadjuvant or adjuvant agent
Significant reductions in the use of bevacizumab + docetaxel in metastatic breast cancer have recently been made by oncologists; further reductions in the use of this combination will occur due to the EMA’s decision
• The use of bevacizumab + paclitaxel, which was unaffected by the recent EMA decision, has had and will have only some minor reductions in usage for metastatic breast cancer. The use of bevacizumab in other tumor types are also relatively unaffected

Patients Expected to Receive Ribulin

To download a free copy of this MDoutlook report (in .pdf format), click here Changing European Paradigms for the Treatment of Metastatic Breast Cancer.

MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader-composed Strategy Councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 51,000+ cancer treaters and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians

For more information about MDoutlook or to receive PowerPoint slides of this report, please email or call +1.404.496.4136.